SAILIFE

Sai Life Science Share Price

₹705.75 -28.55 (-3.89%)

22 Feb, 2025 22:34

SIP TrendupStart SIP in SAILIFE

Start SIP

Performance

  • Low
  • ₹696
  • High
  • ₹740
  • 52 Week Low
  • ₹639
  • 52 Week High
  • ₹809
  • Open Price₹733
  • Previous Close₹734
  • Volume444,199

Investment Returns

  • Over 1 Month -0.97%
  • Over 3 Month + 28.55%
  • Over 6 Month + 28.55%
  • Over 1 Year + 28.55%
SIP Lightning

Smart Investing Starts Here Start SIP with Sai Life Science for Steady Growth!

Invest Now

Sai Life Science Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 106.4
  • PEG Ratio
  • -
  • Market Cap Cr
  • 14,685
  • P/B Ratio
  • 15.2
  • Average True Range
  • 39.95
  • EPS
  • 6.63
  • Dividend Yield
  • 0
  • MACD Signal
  • -8.43
  • RSI
  • 51.83
  • MFI
  • 71.85

Sai Life Science Financials

Sai Life Science Technicals

EMA & SMA

Current Price
₹705.75
-28.55 (-3.89%)
pointer
  • stock-down_img
  • Bullish Moving Average 9
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹692.99
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

713.93 Pivot Speed
  • R3 775.47
  • R2 757.68
  • R1 731.72
  • S1 687.97
  • S2 670.18
  • S3 644.22

What's your outlook on Sai Life Science?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sai Life Sciences, a leading CRDMO, partners with 280+ global pharma and biotech companies to accelerate NCE small molecule programs. across India, UK, USA, and Japan, it ensures quality and compliance through USFDA-certified facilities.

Sai Life Sciences Ltd has an operating revenue of Rs. 1,554.27 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 7% is okay, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 28%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its key moving averages, around 3% and 3% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 9% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 32 which is a POOR score indicating inconsistency in earnings, a RS Rating of 58 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 44 indicates it belongs to a fair industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sai Life Science Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-06 Quarterly Results

Sai Life Science F&O

Sai Life Science Shareholding Pattern

35.24%
10.19%
1.06%
11.72%
0.07%
8.87%
32.85%

About Sai Life Science

  • NSE Symbol
  • SAILIFE
  • BSE Symbol
  • 544306
  • Managing Director & CEO
  • Mr. Krishnam Raju Kanumuri
  • ISIN
  • INE570L01029

Similar Stocks to Sai Life Science

Sai Life Science FAQs

Sai Life Science share price is ₹705 As on 22 February, 2025 | 22:20

The Market Cap of Sai Life Science is ₹14684.5 Cr As on 22 February, 2025 | 22:20

The P/E ratio of Sai Life Science is 106.4 As on 22 February, 2025 | 22:20

The PB ratio of Sai Life Science is 15.2 As on 22 February, 2025 | 22:20

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23